Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gMSC4
- Development stage
- Unknown
- Lead developer
- Two Cells
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
gMSC®4 is an allogeneic mesenchymal stem cell (MSC) therapy developed by Two Cells for the treatment of chronic kidney disease (CKD). The therapy utilizes GMP-grade allogeneic mesenchymal stem cells intended to promote renal tissue regeneration and slow the progression of CKD. It is currently being evaluated in Phase 1 clinical trials and clinical research in collaboration with Hiroshima University. As of late 2024, clinical research involving patients has been conducted to assess the safety and preliminary efficacy of the product in the context of chronic renal failure.
- Brand names
- gMSC®4
- Other names
- gMSC®4 (慢性腎臓病細胞治療製品)
Beyond the preview
Go deeper on gMSC4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gMSC4.